Session Details

SUN05 Controversies Regarding Surgery and Radiation in Merkel Cell Carcinoma Management

Fri, Aug 2, 7:30 AM - 8:30 AM
617
1 CME Available Sunrise Session NEW
View Map

DESCRIPTION

During this session, we will comprehensively address controversial areas in the management of locoregional Merkel cell carcinoma (MCC), relying on up-to-date data and expert panel opinions. We will begin by outlining standard staging procedures and treatment recommendations. Next, we will delve into the evolving landscape of surgical options, including the nuances of narrow versus wide local excision, as well as the utility of Mohs micrographic surgery. This discussion will extend to the indications for sentinel lymph node biopsy and postoperative radiation therapy. Lastly, we will introduce the emerging paradigm of hypo-fractionated radiation therapy. Our expert panel will provide practical tips for tailoring optimal treatment plans that align with individual patient requirements.

LEARNING OBJECTIVES

1.

Summarize the standard treatment options of locoregional Merkel cell carcinoma staging and therapy.

2.

Describe the advantages and drawbacks of wide local excision, Mohs surgery, and radiation therapy.

3.

Apply tailored, ideal treatment regimens to meet specific patient needs.

SCHEDULE

2:30 PM

Overview of locoregional Merkel cell carcinoma treatment options

Paul Nghiem, MD, PhD, FAAD

2:45 PM

Surgical excision of Merkel cell carcinoma

3:00 PM

Radiation therapy for Merkel cell carcinoma

3:15 PM

Panel Discussion, Q&A

SPEAKERS

Martha Laurin Council, MD, MBA, FAAD

Martha Laurin Council, MD, MBA, FAAD

Division of Dermatology, Washington University

Peter Goff

Peter Goff

Seattle VA Medical Center; UW & FHCC Radiation Oncology

Paul Nghiem, MD, PhD, FAAD

Paul Nghiem, MD, PhD, FAAD

Dept of Dermatology; Univ of WA

Song Park, MD, IFAAD

Song Park, MD, IFAAD

SPEAKER DISCLOSURES

Martha Laurin Council, MD, MBA, FAAD

Castle Biosciences – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Sanofi/Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding);

Peter Goff

No financial relationships exist with ineligible companies.

Paul Nghiem, MD, PhD, FAAD

Almirall – Consultant(Honoraria); Bristol-Myers Squibb – Investigator(Grants/Research Funding); EMD Serono – Consultant(Fees); Merck & Co., Inc – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria);

Song Park, MD, IFAAD

EMD Serono – Speaker(Honoraria);